A Phase 1/2 interventional study of Lenvatinib and Lenvatinib in Stage IV Melanoma, sponsored by Eisai Inc.. Completed at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-10.
Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing lenvatinib in Melanoma — 3 open to participants now, 5 under way, none of them phase 3. lenvatinib · Melanoma.
Among the 18 studies testing lenvatinib in Melanoma, this one is the 7th largest by enrollment, is one of 2 that started in 2010, is one of 3 in phase 1/2, and was the 2nd registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →3 of the 18 studies testing lenvatinib in Melanoma are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital
Ages 18–75
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Sites in China
Ages 18–75
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 2
First in 2005; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 41 across the 18 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
10 studies in Melanoma by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 10 studies in Melanoma by Eisai Co., Ltd., this one is the 3rd largest by enrollment, is one of 5 that started in 2010, is one of 2 in phase 1/2, and was the 4th registered.
Eisai Co., Ltd.’s Melanoma studies by the year they started, since 2005.
1 of the studies testing lenvatinib in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03313206Gustave Roussy, Cancer Campus, Grand ParisNeoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing lenvatinib in Melanoma, from their registry updates:
Among Eisai Co., Ltd.’s 10 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary:
Secondary:
-Phase II: To make a preliminary assessment of the efficacy of lenvatinib administered in combination with dacarbazine, compared with dacarbazine alone.
Safety was assessed by monitoring and recording all treatment emergent adverse events (AEs) and serious adverse events (SAEs); regular monitoring of clinical laboratory parameters; periodic measurement of vital signs and electrocardiograms (ECGs); dose limiting toxicities; performance of physical examinations; concomitant medications and procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine
Drug: Lenvatinib · Drug: Dacarbazine
Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine
Drug: Lenvatinib · Drug: Dacarbazine
Participants received dacarbazine
Drug: Dacarbazine
Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
Also known as: E7080
Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
Also known as: E7080
Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
Also known as: Dacarbazine (DTIC)-Dome
Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b)
DLTs were defined as clinically significant adverse events (AEs) occurring less than or equal to 21 days after commencing study treatment and considered by the Investigator to be possibly or probably related to study treatment.
Time frame: From Day 1 through 21 days (one cycle)
Number of Participants With Adverse Events/Serious Adverse Events (AEs/SAEs)
Safety assessments consisted of monitoring and recording all AEs, including all Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0) grades, and SAEs; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); and performance of physical examinations. Details of AEs and SAEs are provided in the reported adverse event section.
Time frame: From signing of informed consent up to 30 days after the last dose, up to approximately 2 years
Progression Free Survival (PFS) (for Phase 2)
PFS was defined as the time from the date of randomization of a participant until (1) the date of first documented progression of such participant's disease based on Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST v. 1.1) or (2) the date of such participant's death due to any cause. Progression was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions, based on Investigator assessment according to RECIST 1.1. If missing assessments, imputed dates were used in the analysis.
Time frame: From the date of randomization until the date of disease progression or death (whichever was earlier) or up to approximately 2 years
Time to Progression (TTP) (for Phase 2)
TTP, defined as the time from the date of randomization until the date of progressive disease.
Time frame: From the date of randomization until disease progression or death or up to approximately 2 years
Overall Survival (OS) (for Phase 2)
OS, defined as the time from the date of randomization until the date of death. Few events of deaths (9 events in the Lenvatinib + Dacarbazine arm and 4 events in the Dacarbazine arm) were reported to calculate the median OS or to draw conclusions regarding the OS.
Time frame: From the date of randomization until death or up to approximately 2 years
Overall Response Rate (ORR) (for Phase 2)
ORR, defined as percentage of participants with best confirmed response (complete response \[CR\] or partial response \[PR\]). A confirmatory scan was required after no less than 4 weeks and no later than 8 weeks, starting on the date that the response was first recorded.
Time frame: From the date of randomization until disease progression or death or up to approximately 2 years
A total of 16 participants were enrolled in the Phase 1b portion of the study; all 16 participants received study treatment. A total of 82 participants were randomized in the Phase 2 portion of the study and a total of 81 participants received treatment. In the Darcarbazine arm, one participant withdrew consent prior to receiving study treatment.
| Milestone | 16 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 1b) | 22 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 2) | Dacarbazine (Phase 2) |
|---|---|---|---|---|---|
| Started | 3 | 7 | 6 | 42 | 39 |
| Completed | 0 | 0 | 0 | 3 | 1 |
| Not completed | 3 | 7 | 6 | 39 | 38 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 1 | 7 | 3 |
| Withdrew: Started a new line of therapy | 2 | 6 | 4 | 25 | 33 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 5 | 1 |
DLTs were defined as clinically significant adverse events (AEs) occurring less than or equal to 21 days after commencing study treatment and considered by the Investigator to be possibly or probably related to study treatment.
| Participants with DLT | 16 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 1b) | 22 mg Lenvatinib + Dacarbazine (Phase 1b) |
|---|---|---|---|
| Participants with DLTs | 0 | 1 | 2 |
| Grade 3 hypertension | 0 | 1 | 1 |
| Grade 3 febrile neutropenia | 0 | 0 | 1 |
| Grade 3 thrombocytopenia | 0 | 0 | 1 |
Safety assessments consisted of monitoring and recording all AEs, including all Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0) grades, and SAEs; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); and performance of physical examinations. Details of AEs and SAEs are provided in the reported adverse event section.
| Participants | 16 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 1b) | 22 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 2) | Dacarbazine (Phase 2) |
|---|---|---|---|---|---|
| AEs | 3 | 7 | 6 | 40 | 31 |
| SAEs | 2 | 4 | 2 | 16 | 1 |
PFS was defined as the time from the date of randomization of a participant until (1) the date of first documented progression of such participant's disease based on Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST v. 1.1) or (2) the date of such participant's death due to any cause. Progression was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions, based on Investigator assessment according to RECIST 1.1. If missing assessments, imputed dates were used in the analysis.
| Weeks | 20 mg Lenvatinib + Dacarbazine (Phase 2) | Dacarbazine (Phase 2) |
|---|---|---|
| Progression Free Survival (PFS) (for Phase 2) | 19.1 (9.57 to 25.57) | 7.0 (5.57 to 15.57) |
TTP, defined as the time from the date of randomization until the date of progressive disease.
Results for this outcome have not been posted.
OS, defined as the time from the date of randomization until the date of death. Few events of deaths (9 events in the Lenvatinib + Dacarbazine arm and 4 events in the Dacarbazine arm) were reported to calculate the median OS or to draw conclusions regarding the OS.
Results for this outcome have not been posted.
ORR, defined as percentage of participants with best confirmed response (complete response \[CR\] or partial response \[PR\]). A confirmatory scan was required after no less than 4 weeks and no later than 8 weeks, starting on the date that the response was first recorded.
Results for this outcome have not been posted.
Collected over From signing of informed consent up to 30 days after the last dose, up to approximately 2 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 16 mg Lenvatinib + Dacarbazine (Phase 1b) | — | 2/3 (66.7%) | 3/3 (100%) |
| 20 mg Lenvatinib + Dacarbazine (Phase 1b) | — | 4/7 (57.1%) | 7/7 (100%) |
| 22 mg Lenvatinib + Dacarbazine (Phase 1b) | — | 2/6 (33.3%) | 6/6 (100%) |
| 20 mg Lenvatinib + Dacarbazine (Phase 2) | — | 16/42 (38.1%) | 40/42 (95.2%) |
| Dacarbazine (Phase 2) | — | 1/39 (2.6%) | 31/39 (79.5%) |
| Event | 16 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 1b) | 22 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 2) | Dacarbazine (Phase 2) |
|---|---|---|---|---|---|
| Cardiac Failure CongestiveCardiac disorders | 1/3 | 0/7 | 0/6 | 0/42 | 0/39 |
| IleusGastrointestinal disorders | 1/3 | 0/7 | 0/6 | 0/42 | 0/39 |
| AstheniaGeneral disorders | 1/3 | 0/7 | 0/6 | 0/42 | 0/39 |
| FatigueGeneral disorders | 1/3 | 0/7 | 0/6 | 0/42 | 0/39 |
| White Blood Cell Count IncreasedInvestigations | 1/3 | 0/7 | 0/6 | 0/42 | 0/39 |
| DehydrationMetabolism and nutrition disorders | 1/3 | 0/7 | 0/6 | 0/42 | 0/39 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/3 | 0/7 | 1/6 | 0/42 | 0/39 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/7 | 1/6 | 1/42 | 0/39 |
| Abdominal PainGastrointestinal disorders | 0/3 | 0/7 | 1/6 | 1/42 | 0/39 |
| Back PainMusculoskeletal and connective tissue disorders | 0/3 | 1/7 | 1/6 | 0/42 | 0/39 |
| Event | 16 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 1b) | 22 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 2) | Dacarbazine (Phase 2) |
|---|---|---|---|---|---|
| HYPERTENSIONVascular disorders | 1/3 | 6/7 | 5/6 | 20/42 | 2/39 |
| NAUSEAGastrointestinal disorders | 2/3 | 5/7 | 4/6 | 16/42 | 11/39 |
| FATIGUEGeneral disorders | 2/3 | 5/7 | 2/6 | 10/42 | 7/39 |
| DECREASED APPETITEMetabolism and nutrition disorders | 1/3 | 5/7 | 0/6 | 10/42 | 1/39 |
| NEUTROPENIABlood and lymphatic system disorders | 2/3 | 3/7 | 2/6 | 10/42 | 4/39 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 2/3 | 3/7 | 2/6 | 5/42 | 1/39 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 2/3 | 3/7 | 1/6 | 6/42 | 1/39 |
| VOMITINGGastrointestinal disorders | 2/3 | 4/7 | 0/6 | 10/42 | 4/39 |
| URINARY TRACT INFECTIONInfections and infestations | 2/3 | 0/7 | 0/6 | 4/42 | 3/39 |
| WEIGHT DECREASEDInvestigations | 2/3 | 1/7 | 0/6 | 3/42 | 0/39 |
A total of 40 participants were randomized in Dacarbazine (Phase 2) arm but only 39 participants received study drug and were included in the safety analysis set.
| Age, Customized(Participants) | 16 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 1b) | 22 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 2) | Dacarbazine (Phase 2) | Total |
|---|---|---|---|---|---|---|
| 18 years and older | 3 | 7 | 6 | 42 | 39 | 97 |
| Sex/Gender, Customized(participants) | 16 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 1b) | 22 mg Lenvatinib + Dacarbazine (Phase 1b) | 20 mg Lenvatinib + Dacarbazine (Phase 2) | Dacarbazine (Phase 2) | Total |
|---|---|---|---|---|---|---|
| Male | 3 | 2 | 4 | 25 | 23 | 57 |
| Female | 0 | 5 | 2 | 17 | 16 | 40 |
The record gives a start of Apr 2010, a primary completion of Jun 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 2 years 4 months after primary completion. A results delay was requested in Aug 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib